GlassScriptPhysician profile
Bernard A Addogoh
NPI 1841534120
$2,489.14
in general payments reported to CMS, 2019-2025
19 companies · $1,473 in 2025
The $1,473 reported for 2025 was more than what 88% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $131 · 2022: $163 · 2023: $139 · 2024: $584 · 2025: $1,473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,195.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $439.96 | 2024-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $311.23 | 2022-2025 | Rexulti, Abilify Mycite |
| Ani Pharmaceuticals, INC. | $261.51 | 2025 | Purified Cortrophin Gel |
| Harmony Biosciences LLC | $233.80 | 2023-2025 | Wakix |
| Alkermes, INC. | $188.22 | 2024-2025 | Lybalvi, Aristada |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $158.01 | 2025 | Caplyta |
| United Therapeutics Corporation | $150.17 | 2024-2025 | Tyvaso |
| Biocryst US Sales Co., LLC | $144.13 | 2022 | |
| Gilead Sciences, INC. | $122.72 | 2025 | |
| Horizon Therapeutics Plc | $92.71 | 2021 | |
| Idorsia Pharmaceuticals US INC | $73.20 | 2023 | Quviviq |
| Abbvie INC. | $70.98 | 2025 | |
| Jazz Pharmaceuticals INC. | $58.31 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $56.76 | 2023-2024 | |
| Avadel Cns Pharmaceuticals, LLC | $53.56 | 2024 | Lumryz |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $27.08 | 2025 | Fanapt |
| Corium, LLC | $19.33 | 2023 | Azstarys |
| Lilly USA, LLC | $14.53 | 2025 | Mounjaro, Zepbound |
| Sunovion Pharmaceuticals INC. | $12.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernard Addogoh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.